398 related articles for article (PubMed ID: 26925683)
1. Cost Effectiveness Analysis of Different Management Strategies between Best Supportive Care and Second-line Chemotherapy for Platinum-resistant or Refractory Ovarian Cancer.
Luealon P; Khempech N; Vasuratna A; Hanvoravongchai P; Havanond P
Asian Pac J Cancer Prev; 2016; 17(2):799-805. PubMed ID: 26925683
[TBL] [Abstract][Full Text] [Related]
2. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
Edwards SJ; Barton S; Thurgar E; Trevor N
Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481
[TBL] [Abstract][Full Text] [Related]
3. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
4. Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A cost-effectiveness analysis.
Rocconi RP; Case AS; Straughn JM; Estes JM; Partridge EE
Cancer; 2006 Aug; 107(3):536-43. PubMed ID: 16804928
[TBL] [Abstract][Full Text] [Related]
5. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of trabectedin plus pegylated liposomal doxorubicin for the treatment of women with relapsed platinum-sensitive ovarian cancer in the UK: analysis based on the final survival data of the OVA-301 trial.
Fisher M; Gore M
Value Health; 2013 Jun; 16(4):507-16. PubMed ID: 23796284
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA).
Hamanishi J; Takeshima N; Katsumata N; Ushijima K; Kimura T; Takeuchi S; Matsumoto K; Ito K; Mandai M; Nakai H; Sakuragi N; Watari H; Takahashi N; Kato H; Hasegawa K; Yonemori K; Mizuno M; Takehara K; Niikura H; Sawasaki T; Nakao S; Saito T; Enomoto T; Nagase S; Suzuki N; Matsumoto T; Kondo E; Sonoda K; Aihara S; Aoki Y; Okamoto A; Takano H; Kobayashi H; Kato H; Terai Y; Takazawa A; Takahashi Y; Namba Y; Aoki D; Fujiwara K; Sugiyama T; Konishi I
J Clin Oncol; 2021 Nov; 39(33):3671-3681. PubMed ID: 34473544
[TBL] [Abstract][Full Text] [Related]
8. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
[TBL] [Abstract][Full Text] [Related]
9. Cost Effectiveness of Chemotherapeutic Agents and Targeted Biologics in Ovarian Cancer: A Systematic Review.
Poonawalla IB; Parikh RC; Du XL; VonVille HM; Lairson DR
Pharmacoeconomics; 2015 Nov; 33(11):1155-85. PubMed ID: 26072142
[TBL] [Abstract][Full Text] [Related]
10. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.
Lawrie TA; Bryant A; Cameron A; Gray E; Morrison J
Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD006910. PubMed ID: 23835762
[TBL] [Abstract][Full Text] [Related]
11. Markov-modeling for the administration of platinum analogues and paclitaxel as first-line chemotherapy as well as topotecan and liposomal doxorubicin as second-line chemotherapy with epithelial ovarian carcinoma.
Fedders M; Hartmann M; Schneider A; Kath R; Camara O; Oelschläger H
J Cancer Res Clin Oncol; 2007 Sep; 133(9):619-25. PubMed ID: 17458562
[TBL] [Abstract][Full Text] [Related]
12. Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041).
Lee JY; Park JY; Park SY; Lee JW; Kim JW; Kim YB; Jeong DH; Lee KB; Kim TH; Lee IH; Choi MC; Kim KH; Kim YM; Lee YJ; Kang S; ; Pujade-Lauraine E
Gynecol Oncol; 2019 Jan; 152(1):61-67. PubMed ID: 30409490
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and toxicity of gemcitabine and pegylated liposomal Doxorubicin in recurrent platinum-resistant/refractory epithelial ovarian cancer.
Karaoglu A; Arslan UY; Ozkan M; Kalender ME; Alici S; Coskun U; Gumus M; Celenkoglu G; Er O; Sevinc A; Buyukberber S; Alkis N; Benekli M;
Asian Pac J Cancer Prev; 2009; 10(1):63-6. PubMed ID: 19469626
[TBL] [Abstract][Full Text] [Related]
14. Pegylated liposomal doxorubicin and gemcitabine in a fixed dose rate infusion for the treatment of patients with poor prognosis of recurrent ovarian cancer: a phase Ib study.
Crespo G; Sierra M; Losa R; Berros JP; Villanueva N; Fra J; Fonseca PJ; Luque M; Fernández Y; Blay P; Sanmamed M; Muriel C; Esteban E; Lacave AJ
Int J Gynecol Cancer; 2011 Apr; 21(3):478-85. PubMed ID: 21436695
[TBL] [Abstract][Full Text] [Related]
15. A cost-effectiveness analysis of chemotherapy for patients with recurrent platinum-sensitive epithelial ovarian cancer.
Case AS; Rocconi RP; Partridge EE; Straughn JM
Gynecol Oncol; 2007 Apr; 105(1):223-7. PubMed ID: 17215031
[TBL] [Abstract][Full Text] [Related]
16. Costs of treatment and outcomes associated with second-line therapy and greater for relapsed ovarian cancer.
Prasad M; Ben-Porat L; Hoppe B; Aghajanian C; Sabbatini P; Chi DS; Hensley ML
Gynecol Oncol; 2004 Apr; 93(1):223-8. PubMed ID: 15047240
[TBL] [Abstract][Full Text] [Related]
17. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR).
Sehouli J; Chekerov R; Reinthaller A; Richter R; Gonzalez-Martin A; Harter P; Woopen H; Petru E; Hanker LC; Keil E; Wimberger P; Klare P; Kurzeder C; Hilpert F; Belau AK; Zeimet A; Bover-Barcelo I; Canzler U; Mahner S; Meier W
Ann Oncol; 2016 Dec; 27(12):2236-2241. PubMed ID: 27789470
[TBL] [Abstract][Full Text] [Related]
18. A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer.
Tas F; Guney N; Derin D; Aydiner A; Topuz E
Int J Clin Oncol; 2008 Apr; 13(2):156-60. PubMed ID: 18463961
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy.
Sehouli J; Stengel D; Oskay G; Camara O; Hindenburg HJ; Klare P; Blohmer J; Heinrich G; Elling D; Ledwon P; Lichtenegger W;
Ann Oncol; 2002 Nov; 13(11):1749-55. PubMed ID: 12419747
[TBL] [Abstract][Full Text] [Related]
20. The Pharmacological Costs of Second-Line Treatments for Recurrent Ovarian Cancer.
Giuliani J; Bonetti A
Int J Gynecol Cancer; 2017 Nov; 27(9):1872-1876. PubMed ID: 28976446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
